{{Drugbox
| drug_name = 
| IUPAC_name = 4-Methyl-''N''-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide
| image = Radotinib.svg
| alt = 
| caption =

<!-- Clinical data -->
| tradename = Supect
| Drugs.com = 
| MedlinePlus = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration =

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number = 926037-48-1
| ATCvet = 
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 16063245
| DrugBank =
| ChemSpiderID = 17222861

<!-- Chemical data -->
| C=27 | H=21 | F=3 | N=8 | O=1
| molecular_weight  = 530.50 g/mol
| StdInChI = 1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)
| StdInChIKey = DUPWHXBITIZIKZ-UHFFFAOYSA-N
| smiles = CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=NC=CN=C5
}}

'''Radotinib''' ([[International Nonproprietary Name|INN]]; trade name '''Supect'''), and sometimes referred to by its investigational name '''IY5511''', is a drug for the treatment of different types of cancer, most notably [[Philadelphia chromosome]]-positive (Ph<sup>+</sup>) [[Chronic myelogenous leukemia|chronic myeloid leukemia]] (CML)<ref>{{cite journal | journal = Annual Reports in Medicinal Chemistry | volume = 48 | pages = 523–524 | title = Radotinib (Anticancer) | chapter = To Market, To Market - 2012 |author1=Joanne Bronson |author2=Amelia Black |author3=T. G. Murali Dhar |author4=Bruce A. Ellsworth |author5=J. Robert Merritt | doi=10.1016/b978-0-12-417150-3.00028-4}}</ref> with resistance or intolerance of other [[Bcr-Abl tyrosine-kinase inhibitor]]s, such as patients resistant or intolerant to [[imatinib]].

Radotinib is being developed by Ilyang Pharmaceutical Co., Ltd of South Korea<ref>http://www.ilyang.co.kr/english/rnd/rnd03.asp</ref> and is co-marketed by Daewoong Pharmaceutical Co. Ltd, in South Korea.<ref>http://www.dailypharm.com/Users/News/EnglishNews.html?NewsID=3108&nStart=1023&mode=&searchValue=</ref> Radotinib completed a multi-national Phase II clinical trial study in 2012<ref>{{cite journal | pmc = 4077080 | pmid=24705186 | doi=10.3324/haematol.2013.096776 | volume=99 | title=Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors | year=2014 | journal=Haematologica | pages=1191–6 |vauthors=Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW }}</ref> and in August 2011, Ilyang initiated a Phase III, multinational, multi-center, open-label, randomized study for first-line indication.<ref>https://clinicaltrials.gov/ct2/show/NCT01511289?term=radotinib&rank=1</ref> Its [[mechanism of action]] involves inhibition of the Bcr-Abl [[tyrosine kinase]]  and of [[platelet-derived growth factor receptor]] (PDGFR).<ref>{{Cite web | url = http://www.cancer.gov/drugdictionary?cdrid=723999 | work = NCI Drug Dictionary | publisher = [[National Cancer Institute]] | title =  Radotinib hydrochloride  }}</ref>

==References==
{{Reflist}}


{{Extracellular chemotherapeutic agents}}
{{Growth factor receptor modulators}}

[[Category:Benzamides]]
[[Category:Imidazoles]]
[[Category:Pyrazines]]
[[Category:Pyrimidines]]
[[Category:Tyrosine kinase inhibitors]]
[[Category:Trifluoromethyl compounds]]


{{Antineoplastic-drug-stub}}